Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.

Vergara C, Ordóñez-Gutiérrez L, Wandosell F, Ferrer I, del Río JA, Gavín R.

Mol Neurobiol. 2015;51(3):1206-20. doi: 10.1007/s12035-014-8793-7. Epub 2014 Jun 26.

PMID:
24965601
2.

A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.

Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM.

Am J Pathol. 2010 Oct;177(4):1977-88. doi: 10.2353/ajpath.2010.100346. Epub 2010 Aug 27.

3.

Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline.

Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B.

Acta Neuropathol. 2016 Dec;132(6):875-895. Epub 2016 Oct 21.

4.

[Alzheimer disease: cellular and molecular aspects].

Octave JN.

Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. French.

PMID:
16768248
5.

Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.

Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM.

J Neurochem. 2007 Aug;102(4):1053-63. Epub 2007 Apr 30.

6.
7.

Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.

Umeda T, Maekawa S, Kimura T, Takashima A, Tomiyama T, Mori H.

Acta Neuropathol. 2014 May;127(5):685-98. doi: 10.1007/s00401-014-1259-1. Epub 2014 Feb 15.

PMID:
24531886
8.

Impact of the cellular prion protein on amyloid-β and 3PO-tau processing.

Schmitz M, Wulf K, Signore SC, Schulz-Schaeffer WJ, Kermer P, Bähr M, Wouters FS, Zafar S, Zerr I.

J Alzheimers Dis. 2014;38(3):551-65. doi: 10.3233/JAD-130566.

PMID:
24028865
9.

The zinc dyshomeostasis hypothesis of Alzheimer's disease.

Craddock TJ, Tuszynski JA, Chopra D, Casey N, Goldstein LE, Hameroff SR, Tanzi RE.

PLoS One. 2012;7(3):e33552. doi: 10.1371/journal.pone.0033552. Epub 2012 Mar 23. Erratum in: PLoS One. 2012;7(6): doi/10.1371/annotation/866da844-12ad-4fef-a57e-92a4549e035c. PLoS One. 2013;8(5). doi:10.1371/annotation/e83fbf22-647f-496f-b27d-5aff26898083. PLoS One. 2012;7(4): doi/10.1371/annotation/57c710a6-83ba-444c-a352-b9f60125f2fa.

10.

Involvement of WAVE accumulation in Abeta/APP pathology-dependent tangle modification in Alzheimer's disease.

Takata K, Kitamura Y, Nakata Y, Matsuoka Y, Tomimoto H, Taniguchi T, Shimohama S.

Am J Pathol. 2009 Jul;175(1):17-24. doi: 10.2353/ajpath.2009.080908. Epub 2009 Jun 4.

11.

SUMO and Alzheimer's disease.

Lee L, Sakurai M, Matsuzaki S, Arancio O, Fraser P.

Neuromolecular Med. 2013 Dec;15(4):720-36. doi: 10.1007/s12017-013-8257-7. Epub 2013 Aug 25. Review.

12.

Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.

Bloom GS.

JAMA Neurol. 2014 Apr;71(4):505-8. doi: 10.1001/jamaneurol.2013.5847. Review.

PMID:
24493463
13.

Ubiquitination and abnormal phosphorylation of paired helical filaments in Alzheimer's disease.

Iqbal K, Grundke-Iqbal I.

Mol Neurobiol. 1991;5(2-4):399-410. Review.

PMID:
1726645
14.

Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.

Sherman MA, LaCroix M, Amar F, Larson ME, Forster C, Aguzzi A, Bennett DA, Ramsden M, Lesné SE.

J Neurosci. 2016 Sep 14;36(37):9647-58. doi: 10.1523/JNEUROSCI.1899-16.2016.

15.

Mouse models of Alzheimer's disease: the long and filamentous road.

Phinney AL, Horne P, Yang J, Janus C, Bergeron C, Westaway D.

Neurol Res. 2003 Sep;25(6):590-600. Review.

PMID:
14503012
16.

Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease.

Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10032-7. Epub 2003 Jul 29.

17.

APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.

Barbero-Camps E, Fernández A, Martínez L, Fernández-Checa JC, Colell A.

Hum Mol Genet. 2013 Sep 1;22(17):3460-76. doi: 10.1093/hmg/ddt201. Epub 2013 May 6.

18.
19.

Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.

Navarrete LP, Pérez P, Morales I, Maccioni RB.

Curr Alzheimer Res. 2011 Sep;8(6):678-85. Review.

PMID:
21605038
20.

Hyperphosphorylation of tau protein by calpain regulation in retina of Alzheimer's disease transgenic mouse.

Zhao H, Chang R, Che H, Wang J, Yang L, Fang W, Xia Y, Li N, Ma Q, Wang X.

Neurosci Lett. 2013 Sep 13;551:12-6. doi: 10.1016/j.neulet.2013.06.026. Epub 2013 Jun 25.

PMID:
23810804

Supplemental Content

Support Center